Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on CYTK stock, giving a Buy rating on January 14.Invest with ...

Cytokinetics, Incorporated has announced the enrollment opening for AMBER-HFpEF, a Phase 2 randomized, placebo-controlled clinical trial evaluating the safety and tolerability of CK-586 in ...

Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.

and is in line for possible payments on sales of omecamtiv mecarbil and follow-up cardiac myosin inhibitor CK-586, in development for heart failure and preserved ejection fraction (HFpEF), if they ...

With just one week of the IHSAA girls basketball regular season left, sectional pairings have been announced to give teams clarity on what their path to a sectional title looks like. Last season, ...